Vedolizumab for stricturing Crohn's disease of the terminal ileum - an international multicenter cohort study - PubMed
3 hours ago
- #Stricturing
- #Vedolizumab
- #Crohn's disease
- Vedolizumab was assessed in adult patients with imaging-confirmed symptomatic ileal stricturing Crohn's disease.
- Study participants had high prior biologic exposure (84%) and many had anastomotic strictures (64%).
- Cumulative intervention rates (endoscopic balloon dilation or surgery) were 23%, 44%, and 50% at 12, 24, and 48 months.
- Symptom resolution occurred in 52% of patients, with 26% experiencing recurrent obstructive symptoms.
- Vedolizumab persistence rates were 82%, 74%, and 59% at 12, 24, and 48 months.
- Anastomotic stricture inversely associated with intervention (HR 0.21) and surgery (HR 0.11).
- Higher obstructive symptom index and prestenotic bowel dilatation linked to recurrent symptoms.
- Elevated baseline CRP associated with vedolizumab discontinuation (HR 1.96).
- Vedolizumab appears effective for terminal ileal strictures, especially in anastomotic strictures without obstruction.